1. The biotech resurrection continues — Industry and FDA begin to hammer out PDUFA VII details — JNJ single-shot COVID-19 vaccine shows early promise — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Nuvasive Stock

Discussion in 'NuVasive' started by Anonymous, Mar 5, 2013 at 11:46 AM.

  1. Anonymous

    Anonymous Guest

    At just under $20 a share this stock is extremely overpriced. It has been rallying since October when it it was around $12 per share.

    What is driving this increase?
     
  2. Anonymous

    Anonymous Guest

    Short term momentum due to the rising market. This stock will eventually head back down to the $11-12 and then maybe even lower.